Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Rovadicitinib in Renal Impairment
NCT06598956Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rovadicitinib in myelofibrosis (MF) (4 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Peak concentration, Area under the concentration-time curve and 5 more. Started Oct 2024; status: completed.
02
Drugs
rovadicitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06598956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598956.